[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Novo Nordisk A/S ADR (NVO)

Novo Nordisk A/S ADR (NVO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

NVO Stock Plummets as Novo Nordisk Heart Drug Fails Late-Stage Trial

Novo Nordisk (NVO) shares are tumbling on Friday after the Danish pharmaceutical giant posted disappointing headline results from a late-stage cardiovascular clinical trial. In its press release, the company said its experimental anti-inflammatory drug, ziltivekimab, failed to hit its primary endpoint of reducing major adverse cardiovascular events in high-risk patients.

Following today’s decline, Novo Nordisk stock is down more than 10% year-to-date. 

Fundamentals

See More
  • Market Capitalization, $K 210,212,192
  • Shares Outstanding, K 4,465,000
  • Annual Sales, $ 46,792 M
  • Annual Income, $ 15,509 M
  • EBIT $ 23,190 M
  • EBITDA $ 26,518 M
  • 60-Month Beta 0.77
  • Price/Sales 4.92
  • Price/Cash Flow 11.01
  • Price/Book 7.25

Options Overview Details

View History
  • Implied Volatility 44.04% (-0.78%)
  • Historical Volatility 40.48%
  • IV Percentile 40%
  • IV Rank 29.78%
  • IV High 64.20% on 10/09/25
  • IV Low 35.49% on 12/31/25
  • Expected Move (DTE 6) 2.65 (5.63%)
  • Put/Call Vol Ratio 0.53
  • Today's Volume 116,309
  • Volume Avg (30-Day) 50,329
  • Put/Call OI Ratio 0.64
  • Today's Open Interest 1,369,868
  • Open Int (30-Day) 1,336,567
  • Expected Range 44.43 to 49.73

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 23 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $0.81
  • Number of Estimates 4
  • High Estimate $0.87
  • Low Estimate $0.77
  • Prior Year $0.97
  • Growth Rate Est. (year over year) -16.49%

Price Performance

See More
Period Period Low Period High Performance
1-Month
46.44 +1.38%
on 07/31/26
52.12 -9.66%
on 07/29/26
-0.86 (-1.79%)
since 06/30/26
3-Month
41.00 +14.83%
on 06/08/26
52.12 -9.66%
on 07/29/26
+4.86 (+11.51%)
since 04/30/26
52-Week
35.12 +34.05%
on 03/30/26
64.16 -26.62%
on 01/23/26
-2.95 (-5.90%)
since 07/30/25

Most Recent Stories

More News
NVO Stock Plummets as Novo Nordisk Heart Drug Fails Late-Stage Trial

Novo Nordisk stock is sinking on a disappointing Phase 3 clinical trial. Here’s how you should play NVO shares following the dip.

NVO : 47.08 (-8.78%)
LLY : 1,148.84 (-0.53%)
HIMS Stock in Focus as FTC Lawsuit Takes Aim at Hims & Hers Business Practices

Hims & Hers shares crashed yesterday as the FTC filed a lawsuit against the telehealth provider. Here’s how you should play HIMS stock at current levels.

META : 556.71 (+3.28%)
HIMS : 27.77 (+2.70%)
NVO : 47.08 (-8.78%)
SNAP : 4.69 (unch)
Novo Nordisk Sues Eli Lilly Over Obesity Drug Advertising Claims

Novo Nordisk ($NVO) filed a lawsuit against Eli Lilly ($LLY), alleging Lilly's advertising for Zepbound and Mounjaro relies on outdated clinical comparisons that understate the performance of Novo's latest...

NVO : 47.08 (-8.78%)
LLY : 1,148.84 (-0.53%)
Next-Generation Diabetes Therapies Are Reshaping Healthcare and Creating MultiBillion-Dollar Revenue Opportunities

EQNX::TICKER_START (OTCQB:AVAI),(NYSE:NVO),(NASDAQ:SNY),(NASDAQ:DXCM),(NASDAQ:TNDM) EQNX::TICKER_END

AVAI : 0.1210 (+5.31%)
TNDM : 19.50 (+2.58%)
NVO : 47.08 (-8.78%)
DXCM : 83.45 (+11.95%)
SNY : 43.08 (+0.44%)
MoneyMasters Podcast: Where to Invest NOW in AI, Biotech, Small Caps, & Gold!

In this timely and actionable episode, Jeffrey Hirsch, John McCamant, and Luke Lloyd discuss the best profit opportunities for the second half of 2026.

GWRE : 151.94 (-0.83%)
CLDX : 38.06 (-1.10%)
PGEN : 6.27 (+5.56%)
NVO : 47.08 (-8.78%)
AKAM : 115.18 (+1.26%)
SNEX : 76.57 (-1.35%)
ORCL : 129.87 (+1.81%)
ABBV : 250.94 (-2.51%)
GDXJ : 95.39 (-3.69%)
RSP : 215.01 (-0.17%)
VKTX : 31.74 (-4.14%)
LLY : 1,148.84 (-0.53%)
As Employers Drop Obesity Drug Coverage, Hims & Hers Could Be the Winner

Hims & Hers Health shares have surged 45% in 30 days on GLP-1 coverage shifts, but overbought technicals, a Hold rating, and rising short interest suggest a pullback may be near.

HIMS : 27.77 (+2.70%)
NVO : 47.08 (-8.78%)
LLY : 1,148.84 (-0.53%)
MSFT Stock Alert: Microsoft Invests $2.5 Billion in AI Implementation Unit

Microsoft shares soar as the behemoth announces a $2.5 billion investment in a new initiative, Microsoft Frontier Co. But does that warrant buying MSFT stock today?

MSFT : 464.72 (+3.02%)
NVO : 47.08 (-8.78%)
UL : 63.41 (-2.85%)
AMZN : 271.58 (+15.32%)
Heavy, Unusual Put Option Volume Today in Novo Nordisk - Is NVO Overvalued?

A Barchart report today shows unusually heavy volume in out-of-the-money (OTM) put options in Novo Nordisk, which makes Ozempic and Wegovy. NVO stock has been moving up, so is it overvalued now?

NVO : 47.08 (-8.78%)
3 Non-Pharma Firms That Could Benefit From the GLP-1 Trend

With GLP-1 usage continuing to rise, a group of unlikely beneficiaries is emerging; stocks in the broader health care sector and even in retail could stand out.

TDOC : 6.71 (+1.98%)
NVO : 47.08 (-8.78%)
OZEM : 31.75 (-2.34%)
LLY : 1,148.84 (-0.53%)
DXCM : 83.45 (+11.95%)
OLLI : 73.47 (+1.00%)
These 3 Quality Stocks Will Make You Want to LEAP on Their Calls

Thursday’s unusual options activity had plenty to choose from. However, it was the LEAPS that were really worth considering for bullish investors. Of the 28 calls over 365 days, these three quality stocks...

SBUX : 105.25 (-0.57%)
NVO : 47.08 (-8.78%)
LLY : 1,148.84 (-0.53%)
PFE : 25.01 (+0.40%)
AMZN : 271.58 (+15.32%)
DIS : 96.19 (+0.03%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Weakening short term outlook on maintaining the current direction.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

Bagsv'rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care...

See More

Key Turning Points

3rd Resistance Point 48.78
2nd Resistance Point 48.19
1st Resistance Point 47.63
Last Price 47.08
1st Support Level 46.48
2nd Support Level 45.89
3rd Support Level 45.33

See More

52-Week High 64.16
Fibonacci 61.8% 53.07
Fibonacci 50% 49.64
Last Price 47.08
Fibonacci 38.2% 46.21
52-Week Low 35.12

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.